Breaking News Instant updates and real-time market news.

AKCA

Akcea Therapeutics

$18.09

-0.85 (-4.49%)

, IONS

Ionis Pharmaceuticals

$54.73

-0.53 (-0.96%)

07:13
10/23/19
10/23
07:13
10/23/19
07:13

Akcea Therapeutics promotes Kyle Jenne to CCO

Akcea Therapeutics (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals (IONS), announced that the company has promoted Kyle Jenne to chief commercial officer. This promotion is part of Akcea's strategy to expand operations amid further investments in the TEGSEDI and WAYLIVRA launches globally, add new antisense assets to the pipeline and support the potential in-licensing of additional investigational therapies to address rare and serious unmet medical needs. Jenne joined Akcea in May 2017 as the U.S. commercial head.

AKCA

Akcea Therapeutics

$18.09

-0.85 (-4.49%)

IONS

Ionis Pharmaceuticals

$54.73

-0.53 (-0.96%)

  • 05

    Nov

  • 06

    Nov

  • 07

    Dec

AKCA Akcea Therapeutics
$18.09

-0.85 (-4.49%)

10/07/19
WELS
10/07/19
UPGRADE
WELS
Outperform
Akcea Therapeutics upgraded to Outperform from Market Perform at Wells Fargo
10/07/19
10/07/19
UPGRADE
Target $25

Outperform
Akcea Therapeutics upgraded to Outperform on Pfizer partnership at Wells Fargo
As previously reported, Wells Fargo analyst Jim Birchenough upgraded Akcea Therapeutics (AKCA) to Outperform from Market Perform following the partnership of AKCEA-ANGPTL3-Lrx with Pfizer (PFE) for development in cardiovascular and metabolic disease indications. The analyst views the partnership as validating of the ANGPTL3 opportunity, with terms "highly favorable" to Akcea, significant market opportunity in NAFLD/NASH/CVD and upfront cash supportive of increased investment in TEGSEDI commercialization, preparation for TTR-LICA and externally focused business development. Birchenough also raised his price target on Akcea's shares to $25 from $24.
10/07/19
STFL
10/07/19
NO CHANGE
Target $31
STFL
Hold
Pfizer deal a 'solid, unexpected' win for Akcea Therapeutics, says Stifel
Stifel analyst Paul Matteis called Akcea Therapeutics' (AKCA) licensing agreement for AKCEA-ANGPTL3-LRx with Pfizer (PFE) a "solid and unexpected win" for the former in the wake of recent management turnover. Pfizer will pay up to $1.3B in milestones, including $250M in cash upfront, noted Matteis, who does not think investors were ascribing "all that much credit" to this asset. Matteis has a Hold rating on Akcea shares with a $31 price target.
10/08/19
BMOC
10/08/19
NO CHANGE
Target $39
BMOC
Outperform
Akcea Therapeutics price target lowered to $39 from $43 at BMO Capital
BMO Capital analyst Do Kim lowered his price target on Akcea Therapeutics (AKCA) to $39, noting that while the company's announcement of a Pfizer (PFE) licensing deal yesterday provides "immediate value" to its third lipid asset, the disclosure of a management transition increases the risk of potential disruptions in commercial operations. The analyst still keeps his Outperform rating on the stock, citing significant upside optionality from its "underappreciated pipeline assets" with multiple catalysts expected in the next six months that could unlock value for shareholders.
IONS Ionis Pharmaceuticals
$54.73

-0.53 (-0.96%)

09/10/19
09/10/19
UPGRADE
Target $80

Outperform
Ionis Pharmaceuticals upgraded to Outperform at Bernstein
As previously reported, Bernstein analyst Vincent Chen upgraded Ionis Pharmaceuticals to Outperform from Market Perform and raised his price target on the shares to $80 from $70. The analyst cites lower Spinraza expectations, with further downside likely limited, and value-creating catalysts for the Huntington's program that seem not so far away. Chen recommends owning the stock going into the upcoming RG6042 OLE readout.
09/23/19
WELS
09/23/19
DOWNGRADE
Target $24
WELS
Market Perform
Akcea Therapeutics downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough downgraded Akcea Therapeutics (AKCA) to Market Perform from Outperform and lowered his price target on the shares to $24 from $44 following senior management turnover and departure of the company's CEO, President and COO. While interim CEO Damien McDevitt brings significant commercial and business development expertise and familiarly with Ionis Pharmaceuticals (IONS)-sourced products, the analyst sees potential disruption to commercial build for key products TEGSEDI and WAYLIVRA stemming from departure of the architects of commercial effort. While Ionis Pharmaceuticals has committed to providing additional antisense oligonucleotide therapeutics to Akcea to commercialize, Birchenough believes the process to identify ASO candidates could take 6 months or longer, will be balanced by Ionis goal to retain its own wholly owned assets, is difficult to assess value without knowing terms and may require additional investment.
10/10/19
WELS
10/10/19
NO CHANGE
Target $120
WELS
Outperform
Ionis Pharmaceuticals price target raised to $120 from $90 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Ionis Pharmaceuticals to $120 from $90 on ASO pipeline review. While current value and near-term focus remains on approved products SPINRAZA, TEGSEDI and WAYLIVRA, as well as regular R&D revenues, the analyst believes that greater value may exist from its growing ASO pipeline. Specifically, with an estimated base value for existing Ionis product and R&D revenues of $58/share, he estimates an additional $62/share in probability adjusted pipeline value. Birchenough reiterates an Outperform rating on the shares.
10/15/19
CANT
10/15/19
NO CHANGE
Target $65
CANT
Neutral
Cantor keeps Neutral on Ionis after Roche boosts Phase 3 study size
Roche (RHHBY) disclosed yesterday that the size of the RG6042 Phase 3 trial in Huntington's increased from 660 people to 801, Cantor Fitzgerald analyst Eliana Merle tells investors in a research note. Per company comments, this is driven by high patient demand and potential to increase statistical power, particularly for the Q16W dose, adds the analyst. Merle, however, thinks investors might see this change as suggesting the Phase 3 needed more patients for sufficient powering. For her part, the analyst continues to see Huntington's as a challenging indication to study in a clinical trial setting. The higher patient number should improve the likelihood of statistical success, however, says Merle. The analyst, who believes Huntington's is the key stock focus for Ionis Pharmaceuticals investors, keeps a Neutral rating on Ionis shares with a $65 price target.

TODAY'S FREE FLY STORIES

LMB

Limbach Holding

$4.60

0.01 (0.22%)

17:06
11/14/19
11/14
17:06
11/14/19
17:06
Earnings
Limbach Holding reports Q3 EPS (44c), two estimates 20c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

ACB

Aurora Cannabis

$3.29

-0.25 (-7.06%)

17:06
11/14/19
11/14
17:06
11/14/19
17:06
Hot Stocks
Aurora Cannabis reports Q1 production volume up 43% from Q4 at 41.4K kg »

CEO Terry Booth says:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

SRPT

Sarepta

$97.45

-3.55 (-3.51%)

17:05
11/14/19
11/14
17:05
11/14/19
17:05
Syndicate
Breaking Syndicate news story on Sarepta »

Sarepta files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACB

Aurora Cannabis

$3.29

-0.25 (-7.06%)

17:04
11/14/19
11/14
17:04
11/14/19
17:04
Earnings
Aurora Cannabis reports Q1 cannabis net revenue down 25% from Q4 at $70.8M »

Reports Q1 total net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

OXY

Occidental Petroleum

$37.76

-0.36 (-0.94%)

, RH

RH

$175.19

1.98 (1.14%)

17:03
11/14/19
11/14
17:03
11/14/19
17:03
Hot Stocks
Berkshire Hathaway takes position in RH, lowers stake in Apple »

Warren Buffett's…

OXY

Occidental Petroleum

$37.76

-0.36 (-0.94%)

RH

RH

$175.19

1.98 (1.14%)

WFC

Wells Fargo

$53.50

0.23 (0.43%)

PSX

Phillips 66

$119.43

1 (0.84%)

SIRI

Sirius XM

$6.98

0.085 (1.23%)

AAPL

Apple

$262.66

-1.86 (-0.70%)

BAC

Bank of America

$32.74

-0.04 (-0.12%)

KO

Coca-Cola

$52.64

0.24 (0.46%)

AXP

American Express

$120.95

0.68 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 14

    Jan

  • 15

    Jan

CPG

Crescent Point Energy

$3.96

0.035 (0.89%)

17:02
11/14/19
11/14
17:02
11/14/19
17:02
Hot Stocks
Crescent Point Energy to sell Sasketchewan gas infrastructure assets for $500M »

Crescent Point Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VVV

Valvoline

$23.05

0.035 (0.15%)

17:00
11/14/19
11/14
17:00
11/14/19
17:00
Hot Stocks
Valvoline raises quarterly dividend 7% to 11.3c per share »

Valvoline announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

SYY

Sysco

$81.51

0.27 (0.33%)

17:00
11/14/19
11/14
17:00
11/14/19
17:00
Hot Stocks
Sysco raises quarterly diviend to 45c from 39c per share »

The new dividend is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

NGVC

Natural Grocers

$9.28

0.64 (7.41%)

16:57
11/14/19
11/14
16:57
11/14/19
16:57
Hot Stocks
Natural Grocers issues recall on organic soybeans due to mold »

Cottage Natural Food…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

KMPH

KemPharm

$0.51

0.0229 (4.66%)

16:56
11/14/19
11/14
16:56
11/14/19
16:56
Earnings
KemPharm reports Q3 diluted EPS 6c, consensus (19c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

MTD

Mettler-Toledo

$713.22

-8.48 (-1.18%)

16:55
11/14/19
11/14
16:55
11/14/19
16:55
Initiation
Mettler-Toledo initiated  »

Mettler-Toledo initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAT

Waters

$213.34

-0.06 (-0.03%)

16:52
11/14/19
11/14
16:52
11/14/19
16:52
Initiation
Waters initiated  »

Waters initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBSE

NeuBase Therapeutics

$5.19

0.04 (0.78%)

, HGV

Hilton Grand Vacations

$35.29

0.05 (0.14%)

16:51
11/14/19
11/14
16:51
11/14/19
16:51
Hot Stocks
Greenlight raises stake in Brighthouse, cuts stake in Dillard's »

David Einhorn's…

NBSE

NeuBase Therapeutics

$5.19

0.04 (0.78%)

HGV

Hilton Grand Vacations

$35.29

0.05 (0.14%)

KAR

KAR Auction

$22.80

0.88 (4.01%)

VAL

Valaris

$4.09

-0.25 (-5.76%)

CARS

Cars.com

$12.56

0.48 (3.97%)

BHF

Brighthouse Financial

$40.06

0.055 (0.14%)

CC

Chemours

$18.54

0.2 (1.09%)

GM

General Motors

$36.80

-0.4 (-1.08%)

ADNT

Adient

$20.37

-0.705 (-3.35%)

DDS

Dillard's

$77.04

9.235 (13.62%)

GRBK

Green Brick

$11.69

0.03 (0.26%)

AER

AerCap

$59.97

-0.39 (-0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

BGNE

BeiGene

$195.90

-1.25 (-0.63%)

16:50
11/14/19
11/14
16:50
11/14/19
16:50
Hot Stocks
Breaking Hot Stocks news story on BeiGene 

BeiGene trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 27

    Feb

PAYS

Paysign

$11.27

-0.56 (-4.73%)

16:47
11/14/19
11/14
16:47
11/14/19
16:47
Initiation
Paysign initiated  »

Paysign initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$117.90

0.945 (0.81%)

16:47
11/14/19
11/14
16:47
11/14/19
16:47
Hot Stocks
Pennsylvania American Water to acquire Kane Authority wastewater assets »

Pennsylvania American…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVTR

Avantor

$15.98

0.36 (2.30%)

16:46
11/14/19
11/14
16:46
11/14/19
16:46
Initiation
Avantor initiated  »

Avantor initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EUSHF

Eurocash

$0.00

(0.00%)

16:46
11/14/19
11/14
16:46
11/14/19
16:46
Downgrade
Eurocash rating change  »

Eurocash downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:45
11/14/19
11/14
16:45
11/14/19
16:45
General news
Breaking General news story  »

Dallas Federal Reserve…

16:45
11/14/19
11/14
16:45
11/14/19
16:45
General news
Breaking General news story  »

Dallas Federal Reserve…

TMO

Thermo Fisher

$300.82

0.92 (0.31%)

16:44
11/14/19
11/14
16:44
11/14/19
16:44
Initiation
Thermo Fisher initiated  »

Thermo Fisher initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 07

    Dec

RH

RH

$175.19

1.98 (1.14%)

16:41
11/14/19
11/14
16:41
11/14/19
16:41
Hot Stocks
Breaking Hot Stocks news story on RH »

RH jumps 6% to $186.56…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTON

Peloton

$25.96

0.015 (0.06%)

, ALC

Alcon

$58.90

-0.17 (-0.29%)

16:41
11/14/19
11/14
16:41
11/14/19
16:41
Hot Stocks
Soros adds to Celgene position, lowers Caesars stake, exits Disney »

George Soros' Soros…

PTON

Peloton

$25.96

0.015 (0.06%)

ALC

Alcon

$58.90

-0.17 (-0.29%)

ALLY

Ally Financial

$30.83

0.15 (0.49%)

ORCC

Owl Rock

$18.20

0.2 (1.11%)

DIS

Disney

$147.19

-1.5 (-1.01%)

VMC

Vulcan Materials

$141.66

3.04 (2.19%)

CAG

Conagra Brands

$28.45

0.13 (0.46%)

CELG

Celgene

$110.03

-0.42 (-0.38%)

EPC

Edgewell Personal Care

$31.40

-0.815 (-2.53%)

VST

Vistra Energy

$26.34

0.34 (1.31%)

NLY

Annaly Capital

$9.11

0.035 (0.39%)

C

Citi

$73.85

-0.06 (-0.08%)

CZR

Caesars

$12.86

0.09 (0.70%)

VICI

VICI Properties

$24.58

0.24 (0.99%)

MS

Morgan Stanley

$48.61

0.22 (0.45%)

ADM

Archer Daniels

$42.78

-0.04 (-0.09%)

LBRDK

Liberty Broadband

$119.07

0.36 (0.30%)

GOOGL

Alphabet Class A

$1,309.61

13.61 (1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 02

    Dec

  • 04

    Dec

  • 06

    Dec

  • 07

    Dec

  • 09

    Dec

  • 14

    Jan

  • 25

    Mar

  • 04

    Apr

RH

RH

$175.19

1.98 (1.14%)

, OXY

Occidental Petroleum

$37.76

-0.36 (-0.94%)

16:40
11/14/19
11/14
16:40
11/14/19
16:40
Hot Stocks
Breaking Hot Stocks news story on RH, Occidental Petroleum »

Buffett's Berkshire…

RH

RH

$175.19

1.98 (1.14%)

OXY

Occidental Petroleum

$37.76

-0.36 (-0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:39
11/14/19
11/14
16:39
11/14/19
16:39
General news
Fed Balance Sheet Level data reported »

Week of 11/13 Fed Balance…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.